Diabetic nephropathy primary prevention

Jump to navigation Jump to search

Diabetic nephropathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Diabetic nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Diabetic nephropathy primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Diabetic nephropathy primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diabetic nephropathy primary prevention

CDC on Diabetic nephropathy primary prevention

Diabetic nephropathy primary prevention in the news

Blogs on Diabetic nephropathy primary prevention

Directions to Hospitals Treating Diabetic nephropathy

Risk calculators and risk factors for Diabetic nephropathy primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2]

Overview

Primary prevention of diabetic nephropathy is aimed at preventing diabetes in the first place.

Primary Prevention

  • Primary prevention of diabetic nephropathy is aimed at preventing diabetes in the first place. This is achieved through encouraging weight loss and exercise among the general population.[1][2][3][4]
  • Currently, there is insufficient evidence for the use of drugs, such as metformin, as means for primary prevention of diabetes.[1][5]

References

  1. 1.0 1.1 Ayodele OE, Alebiosu CO, Salako BL (2004). "Diabetic nephropathy--a review of the natural history, burden, risk factors and treatment". J Natl Med Assoc. 96 (11): 1445–54. PMC 2568593. PMID 15586648.
  2. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M (2001). "Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance". N. Engl. J. Med. 344 (18): 1343–50. doi:10.1056/NEJM200105033441801. PMID 11333990.
  3. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV (1997). "Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study". Diabetes Care. 20 (4): 537–44. PMID 9096977.
  4. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (2002). "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin". N. Engl. J. Med. 346 (6): 393–403. doi:10.1056/NEJMoa012512. PMC 1370926. PMID 11832527.
  5. Sherwin RS, Anderson RM, Buse JB, Chin MH, Eddy D, Fradkin J, Ganiats TG, Ginsberg H, Kahn R, Nwankwo R, Rewers M, Schlessinger L, Stern M, Vinicor F, Zinman B (2003). "The prevention or delay of type 2 diabetes". Diabetes Care. 26 Suppl 1: S62–9. PMID 12502620.

Template:WH Template:WS